Umbilical cord-derived mesenchymal stem cells for frailty: a phase 2 randomized trial

Researchers tested cells taken from umbilical-cord tissue in people with frailty, meaning reduced strength and physical reserve. This was a randomized trial, so people were assigned by chance to receive the treatment or a comparison treatment. It was a phase 2 study, an early test of whether a treatment works and is safe. The supplied record does not report how many people took part, what the comparison was, or what happened to participants.

What this means for you: This record is not enough to decide whether the treatment works or is worth buying. Be cautious about clinics selling these stem-cell treatments until full results show clear benefits and acceptable risks.